Abstract
7‐11 November 2010, Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, UK
Highlights
Genotypic tropism results were available for 88 patients from viral RNA sequences and for 53 patients from proviral DNA sequences
In the intent to treat (ITT) analysis 70% of the patients were successfully treated at week 24, defined as a viral load decline of at least 3 logs or a viral load below detection limit of 50 copies/ml
In the subgroup of patients where only a genotypic tropism test from proviral DNA was available 86% of the patients had a viral load below detection limit of 50 copies/ml (70% at baseline)
Summary
Before initiating an antiretroviral combination therapy which includes Maraviroc as one of its components, a coreceptor tropism test has to be performed. As Maraviroc is only effective against HIV strains that are using CCR5 as coreceptor a thoroughly validated and reliable assay should be performed. In case of treatment change due to toxicity, testing should be possible using proviral DNA
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
